Unveiling 6 Analyst Insights On Intellia Therapeutics
Unveiling 6 Analyst Insights On Intellia Therapeutics
揭示Intellia Therapeutics的6個分析師見解
Analysts' ratings for Intellia Therapeutics (NASDAQ:NTLA) over the last quarter vary from bullish to bearish, as provided by 6 analysts.
過去一季度，6位分析師對intellia therapeutics（納斯達克: NTLA）的評級從看好到謹慎不同。
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
以下表格總結了分析師們最近的評級，揭示了過去30天內情緒的變化並將其與前幾個月進行了比較。
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $63.0, a high estimate of $120.00, and a low estimate of $29.00. Observing a downward trend, the current average is 8.16% lower than the prior average price target of $68.60.
分析師通過對12個月價格目標的評估提供更深入的見解，揭示出平均目標價格爲63.0美元，最高估價爲120.00美元，最低估價爲29.00美元。觀察到一個下降趨勢，目前的平均價格比之前的68.60美元的平均價格目標低8.16%。
Analyzing Analyst Ratings: A Detailed Breakdown
分析分析師評級：詳細剖析
The standing of Intellia Therapeutics among financial experts is...
通過深入探索分析師...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。